KR20230116942A - 항hla-dq2.5 항체 및 셀리악병의 치료를 위한 그의사용 - Google Patents

항hla-dq2.5 항체 및 셀리악병의 치료를 위한 그의사용 Download PDF

Info

Publication number
KR20230116942A
KR20230116942A KR1020237024631A KR20237024631A KR20230116942A KR 20230116942 A KR20230116942 A KR 20230116942A KR 1020237024631 A KR1020237024631 A KR 1020237024631A KR 20237024631 A KR20237024631 A KR 20237024631A KR 20230116942 A KR20230116942 A KR 20230116942A
Authority
KR
South Korea
Prior art keywords
seq
cdr
amino acid
variable region
antibody variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237024631A
Other languages
English (en)
Korean (ko)
Inventor
유리 이카와
유우 오쿠라
아키히코 미조로키
Original Assignee
추가이 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 추가이 세이야쿠 가부시키가이샤 filed Critical 추가이 세이야쿠 가부시키가이샤
Publication of KR20230116942A publication Critical patent/KR20230116942A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020237024631A 2020-09-18 2021-09-17 항hla-dq2.5 항체 및 셀리악병의 치료를 위한 그의사용 Pending KR20230116942A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2020157873 2020-09-18
JPJP-P-2020-157873 2020-09-18
PCT/JP2021/034240 WO2022059766A1 (en) 2020-09-18 2021-09-17 Anti-hla-dq2.5 antibody and its use for the treatment of celiac disease
KR1020217042982A KR102559128B1 (ko) 2020-09-18 2021-09-17 항hla-dq2.5 항체 및 셀리악병의 치료를 위한 그의 사용

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217042982A Division KR102559128B1 (ko) 2020-09-18 2021-09-17 항hla-dq2.5 항체 및 셀리악병의 치료를 위한 그의 사용

Publications (1)

Publication Number Publication Date
KR20230116942A true KR20230116942A (ko) 2023-08-04

Family

ID=80739984

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237024631A Pending KR20230116942A (ko) 2020-09-18 2021-09-17 항hla-dq2.5 항체 및 셀리악병의 치료를 위한 그의사용
KR1020217042982A Active KR102559128B1 (ko) 2020-09-18 2021-09-17 항hla-dq2.5 항체 및 셀리악병의 치료를 위한 그의 사용

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217042982A Active KR102559128B1 (ko) 2020-09-18 2021-09-17 항hla-dq2.5 항체 및 셀리악병의 치료를 위한 그의 사용

Country Status (16)

Country Link
US (2) US11739153B2 (https=)
EP (1) EP4214236A4 (https=)
JP (2) JP7147030B2 (https=)
KR (2) KR20230116942A (https=)
CN (3) CN117801114A (https=)
AR (1) AR123537A1 (https=)
AU (2) AU2021343008B2 (https=)
CA (1) CA3192661A1 (https=)
CL (1) CL2023000765A1 (https=)
CO (1) CO2023003681A2 (https=)
CR (1) CR20230166A (https=)
IL (1) IL301326A (https=)
MX (1) MX2023002191A (https=)
PE (1) PE20231208A1 (https=)
TW (2) TW202402804A (https=)
WO (1) WO2022059766A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220153847A1 (en) * 2019-04-01 2022-05-19 Chugai Seiyaku Kabushiki Kaisha Anti-hla-dq2.5 antibody
JP7147030B2 (ja) * 2020-09-18 2022-10-04 中外製薬株式会社 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用
US20240400693A1 (en) * 2021-10-08 2024-12-05 Chugai Seiyaku Kabushiki Kaisha Drug formulation of anti-hla-dq2.5 antibody
TW202333781A (zh) * 2021-10-08 2023-09-01 日商中外製藥股份有限公司 抗ｈｌａ－ｄｑ２﹒５抗體製劑
WO2026044027A1 (en) * 2024-08-20 2026-02-26 Victor Raso Major histocompatibility complex peptides as therapeutic targets for autoimmune diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
IL158342A0 (en) 2001-04-12 2004-05-12 Academisch Ziekenhuis Leiden Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides
EP2249801A2 (en) 2008-02-07 2010-11-17 Amgen Inc. Stabilized protein compositions
AU2013204429B9 (en) 2008-11-30 2017-01-05 Immusant, Inc. Compositions and methods for treatment of celiac disease
WO2010141658A1 (en) 2009-06-04 2010-12-09 The Regent Of The University Of Colorado Therapeutic compositions and methods for the prevention of autoimmune diseases
CA2805564A1 (en) 2010-08-05 2012-02-09 Stefan Jenewein Anti-mhc antibody anti-viral cytokine fusion protein
CN104011207B (zh) * 2011-10-31 2018-09-18 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
WO2016202805A2 (en) 2015-06-15 2016-12-22 Consejo Superior De Investigaciones Científicas (Csic) Targeting of prolamin by rnai in bread wheat
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
JP7162607B2 (ja) * 2017-02-27 2022-10-28 中外製薬株式会社 抗ｈｌａ－ｄｑ２．５／８抗体およびセリアック病の治療のためのその使用
EP3692072A4 (en) 2017-10-03 2021-12-22 Chugai Seiyaku Kabushiki Kaisha ANTI-HLA-DQ2.5 ANTIBODIES
GB201802338D0 (en) * 2018-02-13 2018-03-28 Univ Oslo Antigen binding proteins
US20220153847A1 (en) 2019-04-01 2022-05-19 Chugai Seiyaku Kabushiki Kaisha Anti-hla-dq2.5 antibody
JP7147030B2 (ja) 2020-09-18 2022-10-04 中外製薬株式会社 抗ｈｌａ－ｄｑ２．５抗体およびセリアック病の治療のためのその使用

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Am J Clin Nutr 2007; 85: 160-6
Dig Dis Sci 2004; 49:1479-1484
Gastroenterology 2011; 141:610-620
Gastroenterology 2014; 146:1649-58
Gut 2003; 52:960-965
Gut 2005; 54:1217-1223
J Biomed Sci. 2012; 19(1): 88
J Clin Invest. 2007; 117(1):41-49
N Engl J Med 2003; 348:2517-2524
N Engl J Med 2007; 357:1731-1743
Nutrients 2013 Oct 5(10): 3975-3992

Also Published As

Publication number Publication date
AR123537A1 (es) 2022-12-14
CA3192661A1 (en) 2022-03-24
JP2022051553A (ja) 2022-03-31
AU2021343008B2 (en) 2025-11-13
JP7840234B2 (ja) 2026-04-03
CN117801115A (zh) 2024-04-02
EP4214236A1 (en) 2023-07-26
US20220089743A1 (en) 2022-03-24
CN116096757A (zh) 2023-05-09
WO2022059766A1 (en) 2022-03-24
TWI820484B (zh) 2023-11-01
US11739153B2 (en) 2023-08-29
KR102559128B1 (ko) 2023-07-24
US20230357408A1 (en) 2023-11-09
MX2023002191A (es) 2023-03-03
JP7147030B2 (ja) 2022-10-04
AU2021343008A1 (en) 2023-06-01
AU2026200463A1 (en) 2026-02-12
EP4214236A4 (en) 2024-10-30
KR20220153469A (ko) 2022-11-18
IL301326A (en) 2023-05-01
CN117801114A (zh) 2024-04-02
JP2022172276A (ja) 2022-11-15
AU2021343008A9 (en) 2024-10-10
CO2023003681A2 (es) 2023-04-05
PE20231208A1 (es) 2023-08-17
TW202229345A (zh) 2022-08-01
TW202402804A (zh) 2024-01-16
CL2023000765A1 (es) 2023-11-03
CR20230166A (es) 2023-05-31
CN116096757B (zh) 2024-01-12

Similar Documents

Publication Publication Date Title
KR102559128B1 (ko) 항hla-dq2.5 항체 및 셀리악병의 치료를 위한 그의 사용
JP7689495B2 (ja) 抗ｈｌａ－ｄｑ２．５抗体
WO2023058705A1 (ja) 抗ｈｌａ－ｄｑ２．５抗体の製剤
KR102614250B1 (ko) 항hla-dq2.5 항체의 제제
HK40101688A (zh) 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途
HK40101674A (zh) 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途
HK40084713B (zh) 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途
HK40084713A (en) Anti-hla-dq2.5 antibody and its use for the treatment of celiac disease
HK40106801A (zh) 抗hla-dq2.5抗体的药物制剂
EA052398B1 (ru) Антитело к hla-dq2.5 и его применение для лечения глютеновой энтеропатии
HK40062978B (zh) 抗hla-dq2.5抗体
HK40062978A (en) Anti-hla-dq2.5 antibody

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D16 Fast track examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D16-EXM-PA0302 (AS PROVIDED BY THE NATIONAL OFFICE)

D17 Fast track examination accepted

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D17-EXM-PA0302 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302